MA50980A - Application de totarol et composition pharmaceutique contenant du totarol - Google Patents

Application de totarol et composition pharmaceutique contenant du totarol

Info

Publication number
MA50980A
MA50980A MA050980A MA50980A MA50980A MA 50980 A MA50980 A MA 50980A MA 050980 A MA050980 A MA 050980A MA 50980 A MA50980 A MA 50980A MA 50980 A MA50980 A MA 50980A
Authority
MA
Morocco
Prior art keywords
totarol
application
pharmaceutical composition
composition containing
containing totarol
Prior art date
Application number
MA050980A
Other languages
English (en)
Inventor
Mariusz Cieciara
Artur Wrzosek
Original Assignee
Emergopharm Sp Z O O Sp K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergopharm Sp Z O O Sp K filed Critical Emergopharm Sp Z O O Sp K
Publication of MA50980A publication Critical patent/MA50980A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA050980A 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol MA50980A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL422140A PL236429B1 (pl) 2017-07-06 2017-07-06 Zastosowanie totarolu do wytwarzania preparatu do leczenia bakteryjnego zakażenia pochwy i kompozycja farmaceutyczna do zastosowania w leczeniu stanów zapalnych pochwy o podłożu bakteryjnym

Publications (1)

Publication Number Publication Date
MA50980A true MA50980A (fr) 2020-10-14

Family

ID=63518002

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050980A MA50980A (fr) 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol
MA50979A MA50979B1 (fr) 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA50979A MA50979B1 (fr) 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol

Country Status (18)

Country Link
US (1) US11534412B2 (fr)
EP (1) EP3648751B1 (fr)
KR (1) KR20200024921A (fr)
CA (1) CA3066602C (fr)
CL (1) CL2019003720A1 (fr)
DK (1) DK3648751T3 (fr)
ES (1) ES2929646T3 (fr)
HR (1) HRP20221338T1 (fr)
HU (1) HUE060300T2 (fr)
IL (1) IL271875B2 (fr)
LT (1) LT3648751T (fr)
MA (2) MA50980A (fr)
PL (1) PL236429B1 (fr)
PT (1) PT3648751T (fr)
RS (1) RS63728B1 (fr)
SI (1) SI3648751T1 (fr)
UA (1) UA126031C2 (fr)
WO (1) WO2019009739A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948891A (zh) * 2021-06-07 2022-08-30 南通联亚药业股份有限公司 药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL107491B1 (pl) 1977-10-29 1980-02-29 Przemyslowy Instytut Automatyk Czujnik dwustrunowy do pomiaru malych przesuniec
PL201869A1 (pl) 1977-10-29 1979-05-21 Inst Przemyslu Organiczego Sposob wytwarzania masy kablowej odpornej na dzialanie termitow
JP2700071B2 (ja) 1988-06-10 1998-01-19 株式会社資生堂 抗菌剤及びそれを用いた皮膚外用剤、口腔用組成物
PL166898B1 (pl) 1992-02-13 1995-06-30 Akad Medyczna Sposób wytwarzania kompleksu metylocelulozy z kwasem mlekowym
US6534548B1 (en) * 2001-10-02 2003-03-18 Kimberly-Clark Worldwide, Inc. Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria
PL194437B1 (pl) 2002-06-05 2007-05-31 Akademia Medyczna Im Piastow S Sposób wytwarzania kompleksu na bazie kwasu mlekowego
NZ530834A (en) 2004-01-28 2007-06-29 Owen John Catchpole Near-critical extraction of totarol and/or a product containing totarol
US20090312279A1 (en) * 2005-12-23 2009-12-17 Sterilex Technologies, Llc Antimicrobial compositions
EP1925302A1 (fr) * 2006-11-24 2008-05-28 DSMIP Assets B.V. Composition diététique où pharmaceutique contentant de diterpène tricycliques et leurs dérivés pour le traitment de la dépression
EP1925301A1 (fr) * 2006-11-24 2008-05-28 DSMIP Assets B.V. Utilisation de diterpènes tricycliques et de leurs dérivés pour le traitement et la prévention d'affections inflammatoires et/ou des articulations
JP5471335B2 (ja) * 2009-11-17 2014-04-16 ライオン株式会社 口腔バイオフィルム殺菌剤
CA2859519C (fr) * 2011-12-15 2016-08-16 Colgate-Palmolive Company Composition antibacterienne a base de thymol et de totarol
WO2014137231A2 (fr) 2013-03-07 2014-09-12 T2G Biotechnology Limited Formulations d'extrait de totarol et leurs utilisations
DE102013108870A1 (de) * 2013-08-16 2015-02-19 Aimecs Gmbh Mittel zur Reinigung und zum Schutz von technischen Oberflächen
CN104027260A (zh) 2014-06-20 2014-09-10 广州薇美姿个人护理用品有限公司 一种含有桃柘酚的口腔护理用品
CN104688810A (zh) 2014-12-29 2015-06-10 昆明皕凯科技有限公司 一种基于天然植物原料的抗菌组合物及其应用
CN106581687A (zh) * 2016-12-22 2017-04-26 吉林大学 以乳清蛋白为基质的桃柁酚抗菌纳米水凝胶及其制备方法

Also Published As

Publication number Publication date
UA126031C2 (uk) 2022-08-03
CA3066602C (fr) 2024-01-02
RU2020104832A (ru) 2021-08-06
PL422140A1 (pl) 2019-01-14
HRP20221338T1 (hr) 2022-12-23
DK3648751T3 (da) 2022-11-21
MA50979A (fr) 2020-10-14
IL271875B2 (en) 2023-02-01
MA50979B1 (fr) 2022-11-30
US20200289429A1 (en) 2020-09-17
EP3648751A1 (fr) 2020-05-13
LT3648751T (lt) 2022-12-12
PL236429B1 (pl) 2021-01-11
KR20200024921A (ko) 2020-03-09
PT3648751T (pt) 2022-10-20
BR112019027839A2 (pt) 2020-07-07
IL271875A (en) 2020-02-27
RU2020104832A3 (fr) 2021-10-08
SI3648751T1 (sl) 2023-03-31
WO2019009739A4 (fr) 2019-02-28
CL2019003720A1 (es) 2020-05-22
EP3648751B1 (fr) 2022-09-28
ES2929646T3 (es) 2022-12-01
US11534412B2 (en) 2022-12-27
IL271875B (en) 2022-10-01
HUE060300T2 (hu) 2023-02-28
RS63728B1 (sr) 2022-12-30
CA3066602A1 (fr) 2019-01-10
WO2019009739A1 (fr) 2019-01-10

Similar Documents

Publication Publication Date Title
PL3717471T3 (pl) Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób
EP3565550A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3412660A4 (fr) Dérivé de sulfonamide et composition pharmaceutique le contenant
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
EP3914252A4 (fr) Composition pharmaceutique du nilotinib
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
EP3256138A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3666729A4 (fr) Composition contenant du nano-soufre et application associée
EP3505161A4 (fr) Composition pharmaceutique sublinguale d'édaravone et de (+)-2-bornéol
MA50368A (fr) Nouveau dérivé de 1h-pyrazolopyridine et composition pharmaceutique le contenant
EP3603620A4 (fr) Composition de liposome et composition pharmaceutique
EP3613823A4 (fr) Composition contenant un agent réfrigérant et application de ladite composition
EP3323413A4 (fr) Composition pharmaceutique contenant du célécoxib et du tramadol
EP3381451A4 (fr) Composition pharmaceutique utilisée pour réduire la graisse localisée et utilisation de la composition pharmaceutique
EP3429589A4 (fr) Composition pharmaceutique du nilotinib
EP3434285A4 (fr) Composition pharmaceutique et ses utilisations
EP4023227A4 (fr) Composition pharmaceutique et son application
EP3527195A4 (fr) Préparation pharmaceutique contenant du polyéthylène gylcol loxenatide et son procédé de préparation
EP3777866A4 (fr) Composition pharmaceutique et application de cette dernière
EP3434681A4 (fr) Complexe de curcumine-bore et agent pharmaceutique le contenant
EP3453393A4 (fr) Nouveaux dérivés de quinazolinone inhibant la pi3k et composition pharmaceutique en contenant
EP3582759A4 (fr) Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
MA44286A (fr) Formulation pharmaceutique de cinéol et d'amoxicilline
EP3503885A4 (fr) Composition pharmaceutique et procédés d'utilisation